ARCHIVED - The Management of the National Antiviral Stockpile: Options Report

Table of Contents

• Addendum (June 19, 2009)
• Executive Summary
• Recommendations for ensure best practices in stockpile management include:
  • Purpose
  • Background
• Current Context
  • International Comparisons
  • Regulatory Considerations
  • Population Data
  • Increasing Resistance to Oseltamivir
  • Expert Recommendations on the Composition of the Stockpile
  • Roche Exchange Program
  • Other Stockpile Management Considerations
• Mandate #1:  Management of the Expiring Stock
  • OPTION 1:  Purchase new stock, dispose of existing expired oseltamivir stock
  • OPTION 2:  Keep existing oseltamivir stock for 2 years beyond its expiry date, stability test held stock, then purchase replacement
  • OPTION 3:  Exchange expiring Oseltamivir stock through Roche Exchange Program
  • OPTION 4: Combination Option:  Exchange some expiring oseltamivir stock through Roche Exchange program, hold some expired oseltamivir stock for 2 years beyond its expiry date and stability test
• Mandate #2:  Integration of the Technical Recommendations
• Mandate #3:  Best Practice and Other Recommendations
• Glossary of Terms and Definitions
• ACRONYMS
• APPENDIX 1:  AVSMTG TERMS OF REFERENCE
• APPENDIX 2:  SUMMARY OF ANTIVIRALS CONTAINED AND PROPOSED FOR THE NAS
• APPENDIX 3:  PAEDIATRIC OSELTAMIVIR DOSAGE ESTIMATES, BY WEIGHT
• APPENDIX 4:  COMPARISON OF INTERNATIONAL STOCKPILING TRENDS
• APPENDIX 5:  CALCULATIONS FOR NATIONAL ANTIVIRAL STOCKPILE TARGETS
• APPENDIX 6:  SUMMARY OF NATIONAL ANTIVIRAL STOCKPILE COMPOSITION CHANGES
• APPENDIX 7a:  Purchase requirements
• APPENDIX 7b:  Purchase requirements
• REFERENCES